;

This content has been developed by Galderma and is intended for Healthcare Professionals Only

Prescribing information for Azzalure - UK (Botulinum toxin type A) is available by clicking this link.
Prescribing information for Azzalure - Ireland (Botulinum toxin type A) is available by clicking this link.

With over three decades of clinical experience, Azzalure has a well-established safety profile with predictable treatment results help patients feel more attractive and confident.8,12,14,15

View all

** Compound approved for therapeutic use in December 1990 and aesthetic use in April 2009.

References: 1. Alluzience Summary of Product Characteristics; 2. Hilton S, et al. Dermatol Surg. 2022;48(11):1198-202; 3. Gerber PA, et al. Poster presented at IMCAS World Congress. January 2023. Paris, France. 4. Galderma Data on File MA-52573; 5.  Kassir R et al. Dermatol Ther (Heidelb) 2013;3(2):179–189; 6.  Maas C et al. Aesthet Surg J 2012;32(1 Suppl):S8–S29; 7.  Monheit GD et al. Dermatol Surg 2020;46(1):61–69; 8. Moy R et al. Arch Facial Plast Surg 2009;11(2):77–83; 9. Warren H et al. Plast Surg Nurs 2020;40(1):37–44; 10. Brandt F et al. Dermatol Surg 2009;35(12):1893–1901; 11(2):77–83. 11. Rzany B et al. Dermatol Surg 2007;33(1 Spec No):S18–S25; 12. Gubanova E et al. Aesthet Plast Surg 2018;42(6):1672–1680; 13. Azzalure Summary of Product Characteristics; 14.  Molina B et al. J Eur Acad Dermatol Venereol 2015;29(7):1382–1388; 15. Schlessinger J et al. Dermatol Surg 2021;47:504–509.

Prescribing information for Azzalure - UK (Botulinum toxin type A) is available by clicking this link.
Prescribing information for Azzalure - Ireland (Botulinum toxin type A) is available by clicking this link.

 

 

UKI-ALZ-2600009 Date of Production March 2026

 

Adverse events should be reported. For the UK, Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Website:
www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd,
Email: medinfo.uk@galderma.com Tel: +44 (0) 300 3035674